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Pollinex Quattro® and SDT in grass pollen-induced AR in Spain. Findings are con-
firmed by extensive sensitivity analyses.
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Objectives: Endobronchial valve therapy (EBV) is an innovative treatment that 
has been shown to be safe and effective in selected subgroups of patients with 
severe emphysema. The objective of our study was to assess the cost-effectiveness 
of valve treatment in the German health care system when compared to medical 
management. MethOds: Clinical data from a subset of the Endobronchial Valve 
for Emphysema Palliation Trial (VENT) provided information about clinical events, 
health-related quality of life, and disease staging through 12 months. This informa-
tion was subsequently used as input to a previously published Markov model to 
project longer-term disease progression, mortality, and health resource utilization. 
From this combined analysis, we computed the 5-year and 10-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY). Costs 
and effects were discounted at 3% per year. Results: EBV therapy led to clini-
cally meaningful disease restaging at 12 months (37.8% of cohort improved staging, 
compared to 0% in control). Over 5 years, EBV was projected to increase survival 
from 66.4% to 70.7%, and to add 0.22 QALYs. Costs were estimated to increase by € 
10,299, resulting in an ICER of € 46,322/QALY. Over 10 years, 0.41 QALYs were gained 
at additional cost of € 10,425, yielding an ICER of € 25,142/QALY. cOnclusiOns: Our 
model-based analysis suggests that EBV leads to clinically meaningful changes in 
disease staging and progression when compared to medical management, with 
resulting gains in unadjusted and quality-adjusted life expectancy. Relative to the 
acknowledged willingness-to-pay threshold of € 50,000/QALY, our results indicate 
EBV is a cost-effective therapy in the German health care system.
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Objectives: Allergic rhinitis (AR) affects 10-20% of the US population, with treat-
ment costs exceeding $6 billion annually and has been shown to have a substantial 
impact on productivity. In the U. S. AR is estimated to result in 3.5 million lost work 
days and 2 million lost school days annually. AZ/FP is an intranasal formulation 
of azelastine hydrochloride and fluticasone propionate in an advanced delivery 
system indicated for the relief of symptoms of seasonal AR (SAR). Patients treated 
with AZ/FP experience significantly greater and faster symptom relief in compari-
son to first-line therapy in trials, and thus have the potential to positively impact 
workplace productivity. We use an economic model to calculate the economic effects 
on workplace productivity associated with moving AZ/FP from third-tier to second-
tier pricing and reimbursement. MethOds: Population is SAR sufferers seeking 
treatment. AZ/FP is assumed to gain market share annually with second-tier pric-
ing. Time horizon is one year and five years. Four step approach: (1) estimate total 
number of AR-related symptomatic days; (2) calculate total number of AR-related 
episodes per year multiplied by number of days per episode; (3) estimate number of 
these days that occur during a standard 5-day work week; & (4) Estimate proportion 
of AR symptomatic days resulting in absenteeism or presenteeism. Results: For 
a typical health plan, the estimate of expected number of absenteeism and pres-
enteeism days per AZ/FP patient associated with moving AZ/FP from Tier 3 to Tier 
2 resulted in a reduction of 4,729 AR-symptomatic days annually. Total workplace 
cost savings ranged from $168,838 (Year 1) to $190,937 (Year 5), with the proportional 
effects on absenteeism and presenteeism being roughly equal. cOnclusiOns: AZ/
FP offers an appropriate means of adhering to AR practice guidelines and improv-
ing outcomes. This workplace productivity model shows that the added benefits to 
employers could be substantial.
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Objectives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta 
agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was devel-
oped to assess the potential societal cost benefits of improved inhalation technique 
with DuoResp® Spiromax® compared with Symbicort® Turbuhaler®– a DPI delivering 
the same FDC – in the management of adult patients with persistent asthma and 
chronic obstructive pulmonary disease (COPD) in Sweden. MethOds: The eligible 
adult patient population was based on statistics from the National Board of Health 
and Welfare in Sweden. Societal costs (lost productivity) were based on the annual 
number of work-days lost for asthma and COPD patients in Sweden and the United 
Kingdom (UK), respectively, and the average daily cost of sick leave in Sweden. 
Frequency of poor inhalation technique with Symbicort® Turbuhaler® and the sub-
sequent increased risk of unscheduled health care events were taken from a large 
(n= 1,664) cross-sectional, Italian observational study. The estimated reduction in the 
proportion of patients with poor inhalation technique with DuoResp® Spiromax® 
Objectives: Severe asthma is a major cause of morbidity and mortality around 
the world, associated with a heavy societal burden. The aim of this study was to 
evaluate the economic value of omalizumab in the treatment of adult patients 
with severe allergic asthma in Greece, from a societal perspective, based on data 
collected from a clinical trial (INNOVATE) and real-world evidence (RWE) from a 
prospective observational study conducted in Greece. MethOds: A Markov cohort 
model was developed in Microsoft Excel to compare the costs and outcomes of 
omalizumab plus standard therapy (ST, primarily comprised ICS, LABA and SABA) 
versus ST alone. The time horizon was that of a lifetime. Both direct and indirect 
costs were incorporated. Health outcomes considered were Quality Adjusted Life 
Years (QALYs). Costs and QALYs were discounted annually at 3.5%. Unit costs 
were taken from publically available sources. Productivity losses were calculated 
based on published data, while utility values were taken from the INNOVATE 
study. Deterministic and probabilistic sensitivity analyses were undertaken to 
test the robustness of the model results. Results: The addition of omalizumab 
to ST led to an incremental cost per QALY gained of € 27,888 based on INNOVATE 
trial and € 27,255 based on the RWE. The model appeared to be most sensitive to 
changes in the time horizon and the age of retirement. Results of the probabilistic 
sensitivity analysis showed that the probability of omalizumab being cost effec-
tive was 58% and 84%, at a willingness to pay threshold of € 30,000 and € 40,000, 
respectively. cOnclusiOns: Omalizumab appears to be a cost-effective treatment 
option for adult patients with severe allergic asthma compared with ST in Greece, 
confirmed by both trial and real-world data.
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Objectives: To assess the cost-effectiveness (CE) of indacaterol/glycopyrronium 
(QVA149; 85µg/43µg) as a maintenance bronchodilator treatment of adult patients 
with Chronic Obstructive Pulmonary Disease (COPD) versus salmeterol/flutica-
sone (SFC; 50µg/500µg). MethOds: A CE model of micro-simulation over a 3-, 5-, 
10-year and lifetime horizon was developed from the perspective of the Spanish 
National Healthcare System. Patients progress through subsequent COPD stages 
based on their baseline characteristics and considering the natural decline of 
Forced Expiratory Volume in 1 second (FEV1) and exacerbation rate. In the model 
this is counteracted by treatment-associated FEV1 improvement from baseline and 
exacerbation rate reduction associated to each treatment vs. placebo, which were 
obtained by direct and indirect comparison of primary data from TORCH (SFC vs. 
placebo), SHINE (QVA149 vs. placebo) and ILLUMINATE (QVA149 vs SFC) clinical 
trials. The considered outcomes were life years (LY) gained and quality-adjusted 
life years (QALYs). Cost estimates (Euros 2014) include drugs, disease management 
and mild/severe exacerbation expenditures from Spanish health care cost data-
bases and publications with a discount rate of 3% for costs and effects. Results: 
QVA149 has shown to be less costly and more effective than the fixed combination 
of SFC with respect to both LY and QALYs gained. The cost per patient treated with 
QVA149 over a 3-, 5-, 10-year and lifetime period was estimated to be € 108, € 182, 
€ 305, and € 467 lower than with SFC, which resulted from avoiding exacerbation 
costs and decreasing maintenance cost in relation to slowing COPD progression. 
Therefore, QVA149 was estimated to be dominant over SFC with respect to both 
cost-effectiveness and cost-utility. cOnclusiOns: Due to its higher effectiveness 
in improving FEV1 and reducing COPD exacerbations, QVA149 has shown to be 
more cost-effective than SFC.
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Objectives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Pangramin®, Pollinex Quattro®, and symptomatic drug treatment (SDT) on clinical 
effects and health care costs in patients with grass pollen-induced allergic rhinitis 
(AR) in Spain. MethOds: The effects of three years of drug treatment on quality-
adjusted life years (QALYs) and costs were assessed using a Markov model with 
a nine-year time horizon. Symptom score data were extracted, and the relative 
efficacy on QALYs was assessed through a network meta-analysis (i. e. indirect 
comparison) of 3-year, placebo-controlled, clinical trial data. Patient symptom scores 
were translated into the impact on quality of life by means of published sources. 
Costs associated with drug treatment and other health care resources were calcu-
lated. The incremental costs and QALYs gained were generated accordingly. The 
uncertainty around the model outcomes was determined by means of sensitiv-
ity analyses. Results: The base case analysis over 9 years estimated incremental 
QALYs of 0.005 (95%CI: -0.024; 0.038), 0.016 (95%CI: -0.034; 0.063), 0.059 (95%CI: 0.024; 
0.107), and 0.143 (95%CI: 0.102; 0.195) when Oralair® was compared to Grazax®, 
Pangramin®, Pollinex Quattro® and SDT, respectively. Corresponding incremental 
costs were -€ 1,063 (95%CI: -€ 1,306; -€ 779), € 109 (95%CI: €206; € 428), € 572 (95%CI: € 321; 
€ 864), and € 1,360 (95%CI: € 1,110; € 1,649). Hence, Oralair® was predicted as domi-
nant relative to Grazax®, while ICERs of € 6,931/QALY, € 9,703/QALY, and € 9,517/QALY 
were estimated relative to Pangramin®, Pollinex Quattro®, and SDT, respectively. 
Apart from drug costs, the sensitivity analyses suggest that results were mostly 
driven by drug-specific symptom score values, duration of the pollen season, and 
inputs for immunotherapy discontinuation. At a willingness-to-pay threshold of 
€ 20,000, the probability of Oralair® being the most cost-effective treatment option 
is 65%. cOnclusiOns: Oralair® is cost-effective relative to Grazax®, Pangramin®, 
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24.9 years (SD 14.4). Comparing the use of symptomatic medication (rescue and 
daily), diagnostic-tests, unscheduled medical care (allergist and emergency vis-
its) and sick-leave days number associated with SCIT treatment versus no SCIT 
treatment. SCIT treatment vs no SCIT treatment costs ratio was performed: Used 
resources (Symptomatic medication, unscheduled medical care, diagnostic-tests, 
and 3 years SCIT treatment and sick-leave days) were quantified in € . Efficacy 
(decreased resource usage) of first year treatment was assumed during the remain-
ing two years and during a three years follow-up period. Results: After a single 
year of SCIT all quantified resources (emergency and allergist visits, diagnostic tests, 
rescue medication and work absence days) diminished significantly (p< 0.05) from 
baseline. Reductions in resources’ cost: Hospital resources (100% in Hospitalizations; 
82% in additional visits to the allergist; 79% in ER visits). In medication: (56% in 
rescue medication; 63% in daily medication). In diagnostic tests: (75% in spirometry 
testing broncho-dilation; 72% in O2 saturation measuring; 90% in FeNO measuring 
and 81% in chest radiographs. In leave sick days 94%. Ratio of comparative calcu-
lation described as SCIT treatment versus non SCIT treatment (or conventional 
symptomatic treatment) is 0.8. cOnclusiOns: Considering 3 years of SCIT, and 3 
follow up years of sustained efficacy after completing treatment, cost per patient 
SCIT treated is estimated at 20% below to the cost non SCIT treated patient. Direct 
costs are reduced by 64% and indirect costs by 94%. SCIT of hypoallergenic prepara-
tion of dust-mite allows cost savings vs conventional treatment.
RESPiRatoRy-RElatEd diSoRdERS – Patient-Reported outcomes & Patient 
Preference Studies
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Objectives: Improving asthma control has more recently focused on potentially 
modifiable clinical and behavioural characteristics including correct inhaler tech-
nique, treatment of concomitant allergic rhinitis (AR), adherence and smoking. 
This research aimed to establish the relationship of these factors with measures 
of asthma control and overall health status to add to the growing body of evi-
dence helping to optimize asthma management interventions. MethOds: Data 
were drawn from the USA 2013 Respiratory Disease Specific Programme, a cross-
sectional survey of adult asthma patients consulting for routine care. Partial Least 
Squares Path Modelling was used to quantify the inner model relationships between 
latent variables of patient-reported satisfaction of drug delivery, device functionality, 
device feedback (based on groupings of 12 inhaler device attributes), concomitant 
AR, adherence (Morisky Medication Adherence Scale), smoking history (smok-
ing status, years smoked, number smoked per day), patient reported outcomes 
(Asthma Control Test, Jenkins Sleep Questionnaire, EuroQol-5D-3L) and physician-
reported number of asthma exacerbations in the last 12 months. Patients not receiv-
ing inhaled maintenance therapy were excluded. Results: 243 patients met the 
inclusion criteria. All manifest variable loadings were positive, and a minimum 
Cronbach’s Alpha of 0.713 for the latent variables indicated unidimensionality of 
the manifest variables for each of the latent variables. Cross-loadings were also 
supportive of the hypothesised outer model. Better patient outcomes were sig-
nificantly associated with patient satisfaction with drug delivery (p= 0.002), adher-
ence (p= 0.049), negative smoking history (p< 0.001) and absence of concomitant 
AR (p= 0.005). The R2 value for outcomes was 13.3%, and the pseudo goodness of 
fit, which measures the overall prediction performance of the path model, was 
19.5%. cOnclusiOns: Improving patient satisfaction with inhaler drug delivery 
represents one potentially modifiable aspect of asthma management alongside 
appropriate treatment of AR, smoking cessation and improving adherence, which 
are likely to have a positive impact on asthma patient outcomes.
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Objectives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with Chronic Obstructive Pulmonary Disease and 
the influence of patient´ preference. MethOds: Design: Multicenter patients´ pref-
erence trial or comprehensive cohort design ISRCTN15106246. Patients: 465 COPD 
patients (to detect a difference between groups of 25%, 80% statistical power, 95% 
confidence level, 40% expected losses), with inhaled treatment, written consent. 
Non-probabilistic consecutive sampling. Allocation: Patients without strong pref-
erences for a treatment were randomised: RCT group (block randomization), and 
those with strong preferences were given their choice: PPS group. Variables: Primary 
outcomes: Performance of correct inhalation technique. Secondary outcomes: Pick flow, 
Baseline dyspnea index (BDI), Functional status (forced spirometry). Interventions: 
Intervention-A: Written information. A leaflet with the correct inhalation technique 
for the main inhaler devices used in our area. Intervention-B: Intervention-A + indi-
vidual training (by instructors). Follow-up: 12 month, visits: baseline, 1 month, 3rd 
month, 6th month, 12th month. Statiscal analysis: Mean, frequency, 95% confidence 
interval at baseline. Number Needed to Treat for a benefit (NNT) was calculated. 
Intention to treat analysis. Results: Predominance of males (91.4%), mean age 
69.8 years (CI95%, 69.00-70.59); FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed res-
piratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticoster-
compared with Symbicort® Turbuhaler®was based on a conservative assump-
tion. Results: An estimated 167,666 adult patients used Symbicort® Turbuhaler® 
annually in Sweden and were therefore eligible for treatment with DuoResp® 
Spiromax®, with 72,935 of these exhibiting poor inhalation technique. Based on 
the predicted improvement in inhalation technique with DuoResp® Spiromax® 
compared with Symbicort® Turbuhaler® – and assuming a hypothetical uptake of 
DuoResp® Spiromax®reaching 25% in years 4 and 5 – estimated societal cost savings, 
through the avoidance of 147,158 lost productive days, totalled SEK285.4 million 
(€ 31.2 million). cOnclusiOns: DuoResp® Spiromax® has the potential to improve 
inhalation technique compared with Symbicort® Turbuhaler®, which would likely 
result in substantial societal cost savings.
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Objectives: Increased health care resource utilisation (HCRU) is associated with 
inadequately controlled asthma. Here, we evaluate the impact of omalizumab 
on HCRU in patients with moderate or severe persistent asthma. MethOds: A 
retrospective case-crossover study was conducted using the Truven MarketScan 
database. Data between 1-January-2007 to 30-September-2012 was collected for 
analysis. Patients included in the analysis had to have a diagnosis of moderate or 
severe persistent asthma, be ≥ 12 years of age during the analysis period, have had 
2 years of continuous enrolment (1 year pre/post omalizumab index date), and have 
had exposure to omalizumab continuously for ≥ 12 months. All-cause and asthma-
related HCRU during the years, pre and post omalizumab initiation, were compared 
using McNemar tests and 2-sided paired Student’s t test. Data were stratified by 
asthma severity based on NHLBI criteria. Results: A total of 429 patients (mean 
age, 46.6 years; female, 59.0%; Moderate= 340 [79.3%], Severe= 89 [20.7%]) from the 
database were included in the analysis. The use of omalizumab was associated with 
49.3% (p= 0.0003), 54.0% (p= 0.001), and 35.3% (p= 0.1466) reductions in the mean 
number of asthma-related ER visits and 69.2% (p= 0.0005), 65.5% (p= 0.0045), and 
80.0% (p= 0.0449) reduction in the mean number of asthma-related hospitalisations 
among All, Moderate, and Severe asthma patients, respectively. The mean length of 
stay for asthma-related hospitalisations was also reduced to 71.2% (p= 0.0002), 64.5% 
(p= 0.0016), and 90.6% (p= 0.0442) in All, Moderate, and Severe patients respectively. 
All-cause ER visits were reduced by 30.8% (p= 0.0014), 32.5% (p= 0.0045), and 25.0% 
(p= 0.1348), and hospitalisation reduced by 48.9%, 45.2%, and 64.7% (all p≤ 0.0155) in 
All, Moderate, and Severe asthma patients respectively. Cohort analysis of severe 
asthmatics was limited by sample size. cOnclusiOns: In patients with moderate 
persistent asthma, omalizumab use was associated with significant reductions in 
all-cause and asthma-related HCRU.
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Objectives: Correct device technique has a significant influence on the delivery 
of inhaled therapies and can thus impact the control and management of asthma. 
The objective of this literature review was to examine the impact of device handling 
errors on QOL and health care resources to understand the potential value of a 
novel inhaler device for health care systems and patients. MethOds: A literature 
search of articles published 2009–2013 was undertaken using MeSH terms and key 
words in MEDLINE®, supplemented by a grey literature review and searching of 
reference lists. Article selection and relevant data extraction were based on key 
words relating to handling error, QOL, and health care resource use. Results: Of 
575 potentially relevant publications, 22 were selected for in-depth review. Papers 
reported 25–73% of patients make critical handling errors that lead to no-dose or 
reduced-dose delivery on first use of devices. Incorrect inhaler use was four times 
more frequently reported in patients with uncontrolled asthma than in patients 
with controlled asthma. Poor asthma control also impacts resource use: poorly-
controlled patients made twice as many ER visits, and spent 2–3 times more time 
consulting with physicians than controlled patients (either physician visits or 
time speaking to physicians). Asthma control also impacts QOL: poorly-controlled 
patients reported health-state utility (EQ-5D) values of 0.52–0.69, compared to 0.88–
0.93 for well-controlled patients. cOnclusiOns: Handling errors with devices can 
lead to poorly-controlled patients, resulting in reduced QOL and increased health 
care resource use. New inhaler devices represent an opportunity to reduce errors 
and improve asthma control, therefore improving QOL and reducing resource use. 
Further research is required to model the relationship between a reduction in han-
dling error and improved asthma control status, and the subsequent impact on 
resource use and QOL.
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Objectives: Quantifying cost difference between conventional symptomatic treat-
ment of mite allergy and subcutaneous specific immunotherapy (SCIT) with high 
doses of hypoallergenic dust-mite preparation. MethOds: Observational, retro-
spective and multicenter study carried out in Spain in 2013.419 patients diagnosed 
with rhinitis and / or bronchial asthma for mite allergy were retrieved. Mean age 
